Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gaush MeditechFRA:F7Y -2.80%60 Debt-to-EBITDA is 2.45 as of Dec. 2025, which is 9% above its 10-year median of 2.25. GuruFocus rates FRA:F7Y with a GF Score™ of 60/100 and a GF Value™ of €1.44. The stock has 3 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Gaush Meditech ranks worse than 68.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Gaush Meditech's Debt-to-EBITDA or its related term are showing as below:
FRA:F7Y'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -4.54 Med: 2.25 Max: 171.01
Current: 2.82
During the past 7 years, the highest Debt-to-EBITDA Ratio of Gaush Meditech was 171.01. The lowest was -4.54. And the median was 2.25.
FRA:F7Y's Debt-to-EBITDA is ranked worse than 68.79% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:F7Y: 2.82
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Gaush Meditech Debt-to-EBITDA Related Terms
Gaush Meditech Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Gaush Meditech's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F7Y vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Gaush Meditech's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gaush Meditech Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Gaush Meditech's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Gaush Meditech's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Gaush Meditech (FRA:F7Y) has a Debt-to-EBITDA of 2.45 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gaush Meditech. This is near median its historical median of 2.25. According to the industry distribution chart, Gaush Meditech ranks #324 out of 471 companies in the Medical Devices & Instruments industry, placing it in the top 68.8%.
Is Gaush Meditech's Debt-to-EBITDA too high?
Gaush Meditech's current Debt-to-EBITDA of 2.45 is near median its 10-year median of 2.25. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Gaush Meditech's value of 2.45 is 50.3% above this industry median. Based on the distribution chart, Gaush Meditech ranks #324 out of 471 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Gaush Meditech has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Gaush Meditech's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Gaush Meditech ranks #324 out of 471 companies for Debt-to-EBITDA. This places Gaush Meditech in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Gaush Meditech's value of 2.45 is 50.3% above this benchmark. While the company's 10-year median is 2.25 vs. the industry median of 1.63, Gaush Meditech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gaush Meditech's current Debt-to-EBITDA of 2.45 is 50.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Gaush Meditech. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gaush Meditech's current Debt-to-EBITDA is 2.45, which is near median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gaush Meditech stock overvalued right now?
Gaush Meditech (FRA:F7Y) has a current Debt-to-EBITDA of 2.45. The stock's GF Value™ is €1.44, compared to a current price of €0.49 — trading 66.3% below its estimated fair value. The current Debt-to-EBITDA is 2.45, which is near median its 10-year median of 2.25 and 50.3% above the Medical Devices & Instruments industry median of 1.63. Gaush Meditech's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Gaush Meditech (FRA:F7Y), the current Debt-to-EBITDA is 2.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gaush Meditech (FRA:F7Y) Overvalued in 2026?
Based on GuruFocus' analysis, Gaush Meditech stock appears to be undervalued.
The current stock price of €0.49 is trading 66.3% below its estimated GF Value™ of €1.44.
Key valuation signals for FRA:F7Y:
Debt-to-EBITDA: 2.45 (near median its 10-year median of 2.25)
GF Value™: €1.44 vs. price of €0.49 (66.3% below fair value)
Industry Position: 50.3% above the Medical Devices & Instruments median (#324 of 471)
No single metric tells the full story. See the FRA:F7Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gaush Meditech Ltd is a provider of a broad spectrum of manufacture and sale ophthalmic medical devices and provision of technical services. The segments of the company include Proprietary products segment that derives maximum revenue, develops and produces surgical equipment and related supporting software, intra-optical lens, ophthalmic disease diagnosis and treatment equipment and related supporting consumables independently; Distribution products segment sells multi-function diagnostic equipment, ocular fundus diagnosis, surgical and treatment equipment and related supporting consumables produced by ophthalmic medical equipment manufacturers; Technical services segment provides warranty services, maintenance services and other related consumables; and Others segment.
60GF Score
Get the complete analysis for FRA:F7Y
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F7Y has been successfully added to your 
